Introduction
While RT-PCR remains the gold standard for COVID-19 diagnosis, its binary results fail to capture the nuances of disease progression or the severity of lung involvement. Radiologists frequently turn to chest CT scans to fill this gap; however, traditional visual scoring is subjective, time-consuming, and prone to inter-observer variability. As the SARS-CoV-2 virus evolved from the original strain to the Delta variant, understanding how these physical manifestations changed became critical for clinical staging and recovery prediction. This study introduces an automated, AI-driven pipeline to objectively quantify and compare the lung damage caused by these two variants.
Automated AI Pipeline
To move beyond subjective visual assessment, researchers developed a multi-stage computational framework. The core of this system is a 2.5D Segmentation Model. By feeding several adjacent CT slices into a U-Net-based architecture, the model utilizes spatial context to accurately segment lungs and infections without the prohibitive computational costs of full 3D convolutional neural networks (CNNs).
Once segmented, the regions are converted into 3D models (STL format). A novel stereoscopic segmentation algorithm then automatically subdivides these models into five lobes and 18 segments based on the branching patterns of pulmonary arteries and bronchi. This allows for the calculation of the Percentage of Infection (POI) for each specific lobe, which is then mapped to a digitized version of the Kazerooni semi-quantitative scoring system (0–5).
Comparative Analysis: Original vs. Delta
The study analyzed retrospective data from two cohorts: 35 patients with the original strain (91 scans) and 72 patients with the Delta variant (358 scans). Using non-linear regression to fit CT scores against time since symptom onset, several key differences emerged:
- Delayed Peak: The Delta variant exhibited a "slow burn" progression. Lung involvement peaked on day 15 for Delta patients, compared to day 11 for those with the original strain.
- Prolonged Clearance: The median time to reach a stable negative RT-PCR result was significantly longer for Delta (39 days) than for the original strain (22 days, $p < 0.001$). Consequently, Delta patients required longer hospital stays (median 42 vs. 28 days).
- Viral Persistence: Delta patients were nearly twice as likely to experience "re-detectable" positive RT-PCR results after an initial negative test (30.5% vs. 17.1%), suggesting different viral shedding dynamics.
- Spatial Distribution: While both strains primarily affect the lower lobes, the original strain showed higher initial involvement in the right lower lobe. In contrast, the Delta variant showed more persistent lesions in the right middle lobe during the absorption (recovery) phase.
Clinical Implications and Limitations
Based on these findings, the authors propose a revised clinical timeline for the Delta variant: an Early Stage (0–3 days), a Progressive and Peak Stage (4–16 days), and an extended Absorption Stage (17–42 days). This longer duration of lung change and the higher rate of re-detectable viral loads suggest that Delta requires more cautious discharge criteria and longer follow-up periods.
However, the study notes limitations, including the mixed vaccination status of the Delta cohort (41.7% vaccinated vs. 0% in the original group) and data heterogeneity across different hospital CT equipment. Future research will focus on applying this 3D quantification pipeline to newer variants, such as Omicron, to further refine our understanding of COVID-19's evolving clinical signature.
Summary updated